Microbix Biosystems Inc. (MBXBF)
USD 0.26
(1.69%)
USD 0.26
(1.69%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.21 Million CAD | 20.0% |
| 2022 | 8.51 Million CAD | 37.17% |
| 2021 | 6.2 Million CAD | 19.71% |
| 2020 | 5.18 Million CAD | -4.64% |
| 2019 | 5.43 Million CAD | 3.37% |
| 2018 | 5.26 Million CAD | -2.36% |
| 2017 | 5.38 Million CAD | 30.1% |
| 2016 | 4.14 Million CAD | -12.79% |
| 2015 | 4.74 Million CAD | 48.62% |
| 2014 | 3.19 Million CAD | 3.47% |
| 2013 | 3.08 Million CAD | -28.71% |
| 2012 | 4.33 Million CAD | -6.37% |
| 2011 | 4.62 Million CAD | -14.1% |
| 2010 | 5.38 Million CAD | -9.24% |
| 2009 | 5.93 Million CAD | -1.18% |
| 2008 | 6 Million CAD | 40.49% |
| 2007 | 4.27 Million CAD | 12.16% |
| 2006 | 3.81 Million CAD | 49.42% |
| 2005 | 2.55 Million CAD | -3.02% |
| 2004 | 2.62 Million CAD | 16.93% |
| 2003 | 2.24 Million CAD | 20.6% |
| 2002 | 1.86 Million CAD | 8.08% |
| 2001 | 1.72 Million CAD | 3.15% |
| 2000 | 1.67 Million CAD | -70.13% |
| 1999 | 5.6 Million CAD | 24.44% |
| 1998 | 4.5 Million CAD | 95.65% |
| 1997 | 2.3 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 2.58 Million CAD | 2.82% |
| 2024 Q1 | 3.65 Million CAD | 51.19% |
| 2024 Q2 | 2.51 Million CAD | -31.23% |
| 2023 Q2 | 2.4 Million CAD | 0.68% |
| 2023 FY | 10.21 Million CAD | 20.0% |
| 2023 Q4 | 2.41 Million CAD | -19.73% |
| 2023 Q3 | 3 Million CAD | 25.17% |
| 2023 Q1 | 2.38 Million CAD | 4.86% |
| 2022 Q3 | 1.95 Million CAD | -10.21% |
| 2022 Q4 | 2.27 Million CAD | 16.36% |
| 2022 FY | 8.51 Million CAD | 37.17% |
| 2022 Q1 | 2.1 Million CAD | 26.13% |
| 2022 Q2 | 2.17 Million CAD | 3.78% |
| 2021 Q3 | 1.65 Million CAD | 8.15% |
| 2021 FY | 6.2 Million CAD | 19.71% |
| 2021 Q1 | 1.35 Million CAD | 32.35% |
| 2021 Q2 | 1.53 Million CAD | 13.11% |
| 2021 Q4 | 1.66 Million CAD | 0.53% |
| 2020 Q3 | 1.53 Million CAD | 21.07% |
| 2020 Q2 | 1.27 Million CAD | -6.25% |
| 2020 FY | 5.18 Million CAD | -4.64% |
| 2020 Q4 | 1.02 Million CAD | -33.53% |
| 2020 Q1 | 1.35 Million CAD | -5.77% |
| 2019 Q1 | 1.15 Million CAD | -21.22% |
| 2019 Q4 | 1.43 Million CAD | -0.08% |
| 2019 Q3 | 1.44 Million CAD | 2.36% |
| 2019 Q2 | 1.4 Million CAD | 22.23% |
| 2019 FY | 5.43 Million CAD | 3.37% |
| 2018 Q4 | 1.46 Million CAD | 11.8% |
| 2018 Q2 | 1.28 Million CAD | 7.03% |
| 2018 FY | 5.26 Million CAD | -2.36% |
| 2018 Q1 | 1.2 Million CAD | -31.24% |
| 2018 Q3 | 1.3 Million CAD | 1.46% |
| 2017 Q4 | 1.75 Million CAD | 22.24% |
| 2017 FY | 5.38 Million CAD | 30.1% |
| 2017 Q3 | 1.43 Million CAD | 32.2% |
| 2017 Q2 | 1.08 Million CAD | -3.36% |
| 2017 Q1 | 1.12 Million CAD | -22.43% |
| 2016 Q2 | 975.49 Thousand CAD | 60.91% |
| 2016 FY | 4.14 Million CAD | -12.79% |
| 2016 Q1 | 606.24 Thousand CAD | -66.73% |
| 2016 Q3 | 1.11 Million CAD | 14.2% |
| 2016 Q4 | 1.44 Million CAD | 29.73% |
| 2015 Q3 | 937.65 Thousand CAD | -16.03% |
| 2015 FY | 4.74 Million CAD | 48.62% |
| 2015 Q2 | 1.11 Million CAD | 28.08% |
| 2015 Q1 | 871.85 Thousand CAD | -27.17% |
| 2015 Q4 | 1.82 Million CAD | 94.31% |
| 2014 Q4 | 1.19 Million CAD | 89.08% |
| 2014 Q3 | 633.11 Thousand CAD | -2.73% |
| 2014 Q1 | 713.7 Thousand CAD | 10.38% |
| 2014 Q2 | 650.86 Thousand CAD | -8.81% |
| 2014 FY | 3.19 Million CAD | 3.47% |
| 2013 FY | 3.08 Million CAD | -28.71% |
| 2013 Q2 | 739.25 Thousand CAD | -14.35% |
| 2013 Q1 | 863.06 Thousand CAD | 19.17% |
| 2013 Q3 | 760.14 Thousand CAD | 2.82% |
| 2013 Q4 | 646.57 Thousand CAD | -14.94% |
| 2012 Q1 | 912.44 Thousand CAD | -12.21% |
| 2012 FY | 4.33 Million CAD | -6.37% |
| 2012 Q2 | 1.31 Million CAD | 43.83% |
| 2012 Q4 | 724.26 Thousand CAD | -42.02% |
| 2012 Q3 | 1.24 Million CAD | -4.82% |
| 2011 Q3 | 1.22 Million CAD | -7.4% |
| 2011 Q4 | 1.03 Million CAD | -15.25% |
| 2011 FY | 4.62 Million CAD | -14.1% |
| 2011 Q1 | 935.87 Thousand CAD | -9.68% |
| 2011 Q2 | 1.32 Million CAD | 41.51% |
| 2010 Q1 | 1.23 Million CAD | -34.35% |
| 2010 Q3 | 1.65 Million CAD | 13.27% |
| 2010 Q2 | 1.46 Million CAD | 18.88% |
| 2010 FY | 5.38 Million CAD | -9.24% |
| 2010 Q4 | 1.03 Million CAD | -37.45% |
| 2009 Q3 | 1.18 Million CAD | -23.87% |
| 2009 Q4 | 1.87 Million CAD | 58.59% |
| 2009 FY | 5.93 Million CAD | -1.18% |
| 2009 Q2 | 1.55 Million CAD | 14.55% |
| 2009 Q1 | 1.35 Million CAD | 20.86% |
| 2008 FY | 6 Million CAD | 40.49% |
| 2008 Q4 | 1.12 Million CAD | -34.4% |
| 2008 Q1 | 1.43 Million CAD | 35.33% |
| 2008 Q2 | 1.79 Million CAD | 24.95% |
| 2008 Q3 | 1.7 Million CAD | -4.9% |
| 2007 Q4 | 1.06 Million CAD | -25.1% |
| 2007 FY | 4.27 Million CAD | 12.16% |
| 2007 Q3 | 1.41 Million CAD | 37.89% |
| 2007 Q2 | 1.02 Million CAD | 34.76% |
| 2007 Q1 | 763.56 Thousand CAD | -48.47% |
| 2006 FY | 3.81 Million CAD | 49.42% |
| 2006 Q1 | 776.65 Thousand CAD | 37.75% |
| 2006 Q4 | 1.48 Million CAD | 113.86% |
| 2006 Q2 | 859.25 Thousand CAD | 10.63% |
| 2006 Q3 | 692.93 Thousand CAD | -19.36% |
| 2005 Q2 | 499.21 Thousand CAD | -32.84% |
| 2005 Q1 | 743.34 Thousand CAD | -0.52% |
| 2005 Q3 | 744.06 Thousand CAD | 49.05% |
| 2005 Q4 | 563.79 Thousand CAD | -24.23% |
| 2005 FY | 2.55 Million CAD | -3.02% |
| 2004 Q3 | 701.63 Thousand CAD | 28.48% |
| 2004 Q1 | 634.91 Thousand CAD | -15.19% |
| 2004 Q2 | 546.12 Thousand CAD | -13.99% |
| 2004 FY | 2.62 Million CAD | 16.93% |
| 2004 Q4 | 747.2 Thousand CAD | 6.49% |
| 2003 Q3 | 418.99 Thousand CAD | -20.85% |
| 2003 Q2 | 529.33 Thousand CAD | -4.13% |
| 2003 Q1 | 552.14 Thousand CAD | 52.68% |
| 2003 Q4 | 748.65 Thousand CAD | 78.68% |
| 2003 FY | 2.24 Million CAD | 20.6% |
| 2002 Q3 | 562.75 Thousand CAD | 15.07% |
| 2002 FY | 1.86 Million CAD | 8.08% |
| 2002 Q2 | 489.07 Thousand CAD | 8.32% |
| 2002 Q1 | 451.51 Thousand CAD | 11.88% |
| 2002 Q4 | 361.63 Thousand CAD | -35.74% |
| 2001 Q2 | 422.15 Thousand CAD | -10.87% |
| 2001 Q4 | 403.55 Thousand CAD | -5.33% |
| 2001 Q3 | 426.28 Thousand CAD | 0.98% |
| 2001 Q1 | 473.63 Thousand CAD | 27.01% |
| 2001 FY | 1.72 Million CAD | 3.15% |
| 2000 Q4 | 372.9 Thousand CAD | -6.77% |
| 2000 Q3 | 400 Thousand CAD | -33.33% |
| 2000 Q2 | 600 Thousand CAD | 100.0% |
| 2000 Q1 | 300 Thousand CAD | -91.67% |
| 2000 FY | 1.67 Million CAD | -70.13% |
| 1999 Q3 | 600 Thousand CAD | -14.29% |
| 1999 Q4 | 3.6 Million CAD | 500.0% |
| 1999 Q1 | 700 Thousand CAD | 0.0% |
| 1999 Q2 | 700 Thousand CAD | 0.0% |
| 1999 FY | 5.6 Million CAD | 24.44% |
| 1998 Q1 | 1 Million CAD | 42.86% |
| 1998 FY | 4.5 Million CAD | 95.65% |
| 1998 Q4 | - CAD | -100.0% |
| 1998 Q3 | 1.6 Million CAD | -15.79% |
| 1998 Q2 | 1.9 Million CAD | 90.0% |
| 1997 FY | 2.3 Million CAD | 0.0% |
| 1997 Q3 | 600 Thousand CAD | 20.0% |
| 1997 Q2 | 500 Thousand CAD | 0.0% |
| 1997 Q4 | 700 Thousand CAD | 16.67% |
| 1997 Q1 | 500 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 5.974% |
| Skye Bioscience, Inc. | 13.54 Million USD | 24.578% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 72.574% |
| Nascent Biotech, Inc. | 2.22 Million USD | -358.221% |
| Qrons Inc. | 643.67 Thousand USD | -1487.406% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 55.526% |
| CSL Limited | 3.44 Billion USD | 99.704% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 65.426% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -102.651% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1006.406% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 82.211% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2359.274% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1438.82% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -665.129% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2522.859% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 36.18% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 88.226% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -107.766% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3803.993% |
| SQZ Biotechnologies Company | 85.61 Million USD | 88.066% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -250.375% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -580.323% |
| Mesoblast Limited | 5.9 Million USD | -73.124% |
| Marizyme, Inc. | 19.23 Million USD | 46.893% |
| Genus plc | 147.7 Million USD | 93.082% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -16.386% |
| Pharming Group N.V. | 225.49 Million USD | 95.469% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -398.743% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -661.642% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -22.53% |
| ContraFect Corporation | 56.88 Million USD | 82.039% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -131.765% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -590.972% |
| IMV Inc. | 37.7 Million USD | 72.904% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -266.181% |
| MultiCell Technologies, Inc. | 567.42 USD | -1800641.25% |
| ONE Bio Corp. | 6.44 Million USD | -58.565% |
| Accustem Sciences Inc. | 3.74 Million USD | -172.734% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 88.111% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1820.77% |
| Q BioMed Inc. | 3.43 Million USD | -197.32% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 58.658% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -288.875% |
| Biomind Labs Inc. | 994.18 Thousand USD | -927.756% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 89.713% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -480.661% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -52.095% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -448.055% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 40971.064% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -456.798% |
| GB Sciences, Inc. | 1.42 Million USD | -619.303% |
| Alpha Cognition Inc. | 9.7 Million USD | -5.277% |
| HST Global, Inc. | 140.9 Thousand USD | -7151.425% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -808.319% |
| Halberd Corporation | 74.84 Thousand USD | -13552.449% |
| Enzolytics Inc. | 2.17 Million USD | -368.811% |
| Agentix Corp. | 1.37 Million USD | -644.868% |
| Resverlogix Corp. | 12.71 Million USD | 19.621% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -179.885% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.334% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -878.713% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -324.867% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -546.958% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -200.083% |
| AVAX Technologies, Inc. | 7.31 Million USD | -39.773% |
| Zenith Capital Corp. | 8.94 Million USD | -14.254% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.762% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -58552.006% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -316.149% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -5857.568% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -431.924% |
| Kadimastem Ltd | 2.41 Million USD | -323.954% |
| Helix BioMedix, Inc. | 1.97 Million USD | -418.133% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -5530.088% |
| LadRx Corporation | 3.81 Million USD | -168.057% |
| Cell Source, Inc. | 4.32 Million USD | -136.23% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1006.406% |
| NovAccess Global Inc. | 2.46 Million USD | -314.218% |
| Affymax, Inc. | 39.38 Million USD | 74.057% |
| Itoco Inc. | 919.14 Thousand USD | -1011.662% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -141.075% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -813.116% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1742.546% |
| CytoDyn Inc. | 18.05 Million USD | 43.417% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -40496.631% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -4542.793% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -619.666% |
| SYBLEU INC | 160.87 Thousand USD | -6251.33% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -462.553% |
| International Stem Cell Corporation | 5.27 Million USD | -93.849% |
| Bioxytran, Inc. | 3.82 Million USD | -167.47% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -19309.912% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -50127.43% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 71.825% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -531.506% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1288.595% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -228.44% |
| Neutra Corp. | 243.82 Thousand USD | -4090.683% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 41.469% |
| PureTech Health plc | 144.59 Million USD | 92.934% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 50.133% |
| IXICO plc | 4.7 Million USD | -117.076% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -16.151% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 91.322% |
| CSL Limited | 3.89 Billion USD | 99.738% |
| Cellectis S.A. | 97.32 Million USD | 89.501% |